Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-868 in overweight and obese participants with type 2 diabetes mellitus
NCT05110846Phase 2Completed
- Sponsor
- Carmot Therapeutics
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Countries
- 1
01
Overview
A Phase 2 trial of acmopatide in type 2 diabetes mellitus (T2DM), sponsored by Carmot Therapeutics. Started Feb 2022; status: completed.
02
Drugs
acmopatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05110846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110846.